SFTPD and bronchopulmonary dysplasia: The use of SP-D molecules for the treatment of viral and other microbial diseases, as well as chronic diseases such as chronic obstructive pulmonary disease and asthma, and the SP-D deficiency in premature neonates requiring mechanical ventilation to reduce the risk for developing bronchopulmonary dysplasia is very promising (1).